CN101675042B - 新的2-杂芳基取代的苯并噻吩和苯并呋喃709 - Google Patents

新的2-杂芳基取代的苯并噻吩和苯并呋喃709 Download PDF

Info

Publication number
CN101675042B
CN101675042B CN2008800149945A CN200880014994A CN101675042B CN 101675042 B CN101675042 B CN 101675042B CN 2008800149945 A CN2008800149945 A CN 2008800149945A CN 200880014994 A CN200880014994 A CN 200880014994A CN 101675042 B CN101675042 B CN 101675042B
Authority
CN
China
Prior art keywords
alkyl
fluoroalkyl
compound
alkylene
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800149945A
Other languages
English (en)
Chinese (zh)
Other versions
CN101675042A (zh
Inventor
欧万·阿泽尔
布里特-玛丽·斯万
戴维·温斯博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101675042A publication Critical patent/CN101675042A/zh
Application granted granted Critical
Publication of CN101675042B publication Critical patent/CN101675042B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
CN2008800149945A 2007-03-06 2008-03-05 新的2-杂芳基取代的苯并噻吩和苯并呋喃709 Active CN101675042B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89314907P 2007-03-06 2007-03-06
US60/893,149 2007-03-06
PCT/SE2008/050243 WO2008108730A1 (en) 2007-03-06 2008-03-05 Novel 2-heteroaryl substituted benzothiophenes and benzofuranes 709

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100933476A Division CN102617556A (zh) 2007-03-06 2008-03-05 新的2-杂芳基取代的苯并噻吩和苯并呋喃709

Publications (2)

Publication Number Publication Date
CN101675042A CN101675042A (zh) 2010-03-17
CN101675042B true CN101675042B (zh) 2012-06-13

Family

ID=39738510

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800149945A Active CN101675042B (zh) 2007-03-06 2008-03-05 新的2-杂芳基取代的苯并噻吩和苯并呋喃709
CN2012100933476A Pending CN102617556A (zh) 2007-03-06 2008-03-05 新的2-杂芳基取代的苯并噻吩和苯并呋喃709

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100933476A Pending CN102617556A (zh) 2007-03-06 2008-03-05 新的2-杂芳基取代的苯并噻吩和苯并呋喃709

Country Status (23)

Country Link
US (1) US7772256B2 (https=)
EP (1) EP2132201B1 (https=)
JP (1) JP5631009B2 (https=)
KR (1) KR101530392B1 (https=)
CN (2) CN101675042B (https=)
AR (1) AR065599A1 (https=)
AU (1) AU2008221668B2 (https=)
BR (1) BRPI0808503B8 (https=)
CA (1) CA2680157C (https=)
CL (1) CL2008000645A1 (https=)
CO (1) CO6220965A2 (https=)
EC (1) ECSP099641A (https=)
ES (1) ES2615381T3 (https=)
IL (1) IL200524A0 (https=)
MX (1) MX2009009469A (https=)
MY (1) MY147347A (https=)
NZ (1) NZ579157A (https=)
PE (1) PE20090164A1 (https=)
SA (1) SA08290097B1 (https=)
TW (1) TW200901998A (https=)
UA (1) UA98481C2 (https=)
UY (1) UY30951A1 (https=)
WO (1) WO2008108730A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617556A (zh) * 2007-03-06 2012-08-01 阿斯利康(瑞典)有限公司 新的2-杂芳基取代的苯并噻吩和苯并呋喃709

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009260519A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2388255A1 (en) * 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
CA3086668A1 (en) * 2018-02-05 2019-08-08 Universite De Strasbourg Compounds and compositions for the treatment of pain
KR20220044721A (ko) * 2019-08-06 2022-04-11 도메인 테라퓨틱스 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017095A1 (en) * 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
WO2003051859A1 (en) * 2001-12-19 2003-06-26 Amersham Plc Compounds for imaging alzheimer's disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
JP2004520347A (ja) * 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
JP4307001B2 (ja) * 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
ATE425753T1 (de) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
WO2004087641A1 (ja) 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. ヒドラゾン誘導体
KR100710453B1 (ko) 2003-05-13 2007-04-24 에프. 호프만-라 로슈 아게 아데노신 수용체 리간드로서의 2-이미다조-벤조싸이아졸
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2609980C (en) 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
US20080219922A1 (en) 2005-09-12 2008-09-11 Goodman Mark M Alzheimer's Disease Imaging Agents
CN101355940B (zh) 2005-09-16 2013-03-27 匹兹堡大学高等教育联邦体系 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
ATE539069T1 (de) 2005-10-11 2012-01-15 Univ Pittsburgh Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
WO2008118122A2 (en) 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
WO2008091195A1 (en) 2007-01-22 2008-07-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017095A1 (en) * 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
WO2003051859A1 (en) * 2001-12-19 2003-06-26 Amersham Plc Compounds for imaging alzheimer's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617556A (zh) * 2007-03-06 2012-08-01 阿斯利康(瑞典)有限公司 新的2-杂芳基取代的苯并噻吩和苯并呋喃709

Also Published As

Publication number Publication date
AR065599A1 (es) 2009-06-17
AU2008221668A1 (en) 2008-09-12
JP5631009B2 (ja) 2014-11-26
EP2132201B1 (en) 2016-11-16
ECSP099641A (es) 2009-10-30
CA2680157A1 (en) 2008-09-12
AU2008221668B2 (en) 2011-03-31
BRPI0808503B1 (pt) 2020-09-29
KR20090117892A (ko) 2009-11-13
EP2132201A1 (en) 2009-12-16
CA2680157C (en) 2016-04-12
MX2009009469A (es) 2009-09-15
UY30951A1 (es) 2008-10-31
CN102617556A (zh) 2012-08-01
CO6220965A2 (es) 2010-11-19
JP2010520276A (ja) 2010-06-10
ES2615381T3 (es) 2017-06-06
IL200524A0 (en) 2010-04-29
US7772256B2 (en) 2010-08-10
UA98481C2 (en) 2012-05-25
NZ579157A (en) 2012-04-27
US20080221149A1 (en) 2008-09-11
BRPI0808503A2 (pt) 2014-08-19
TW200901998A (en) 2009-01-16
CL2008000645A1 (es) 2008-10-24
EP2132201A4 (en) 2011-05-25
BRPI0808503B8 (pt) 2021-05-25
MY147347A (en) 2012-11-30
WO2008108730A1 (en) 2008-09-12
RU2009133257A (ru) 2011-04-20
CN101675042A (zh) 2010-03-17
PE20090164A1 (es) 2009-05-03
KR101530392B1 (ko) 2015-06-22
SA08290097B1 (ar) 2011-10-29

Similar Documents

Publication Publication Date Title
CN101675042B (zh) 新的2-杂芳基取代的苯并噻吩和苯并呋喃709
CN101506201B (zh) 新的杂芳基取代的苯并*唑类衍生物
CN101410393B (zh) 新颖的杂芳基取代的苯并噻唑
CN101641354A (zh) 杂芳基取代的新咪唑并[1,2-a]吡啶衍生物
CN101636395A (zh) 新的2-杂芳基取代的吲哚695
RU2472789C2 (ru) Новые 2-гетероарил-замещенные бензотиофены и бензофураны 709

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant